IOVA

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2009, for Genesis Biopharma, Inc. (formerly Freight Management Corp.). The company was originally incorporated in 2007 as a freight management technology firm but had no revenue and minimal operations during the reporting period. On March 15, 2010, subsequent to the reporting period, the company consummated a reverse merger and asset acquisition to transform into a biopharmaceutical company focused on the development of anti-CD55 antibodies (VG102) for cancer treatment.

Key Financial Metrics

Debt and Liquidity: The company had no formal debt but owed $23,120 to a director for operating expenses. This amount is unsecured, interest-free, and has no fixed repayment terms. As of December 31, 2009, cash on hand was $8,257.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately 72% from $57,140 in 2008 to $15,772 in 2009. This was driven primarily by the elimination of database development costs ($30,250 in 2008 vs. $0 in 2009) and a 44% reduction in general and administrative expenses.
• Liability Increase: Current liabilities increased significantly from $3,328 to $23,120, almost entirely due to an increase in amounts due to a director ($3,320 to $23,120).
• Going Concern: The company moved from a positive stockholders' equity position in 2008 ($2,284) to a deficit in 2009 ($(13,488)). Auditors issued a "going concern" opinion, citing substantial doubt about the company's ability to continue operations without additional financing.

Outlook, Risks, and Subsequent Events

Subsequent Events (Post-2009):

• Merger and Rebranding: On March 15, 2010, the company merged with a subsidiary and changed its name to Genesis Biopharma, Inc., pivoting from freight management to biopharmaceuticals.
• Asset Acquisition: Acquired the "Anti-CD55 Antibody Program" from Hamilton Atlantic in exchange for 20,960,016 shares of common stock.
• Licensing: Entered an exclusive license agreement with Cancer Research Technology Limited (CRT) for anti-CD55 antibody technology, agreeing to pay GBP 30,000 in initial royalties plus milestone payments.
• Capital Raise: Completed a private placement on March 15, 2010, raising $400,000 for 12,799,968 shares.

Outlook and Risks:

• Capital Needs: Management anticipates spending between $500,000 and $1,000,000 in the coming year for drug development. They believe existing cash resources (as of the filing date) would sustain operations for only approximately six months.
• Regulatory Risk: As a development-stage biopharmaceutical company, the firm faces significant risks related to FDA approval, clinical trial outcomes, and the high cost of development.
• Internal Controls: Management identified material weaknesses in internal controls, specifically the lack of a functioning audit committee and a lack of independent directors, though remediation steps were initiated in March 2010.

Investor Verification Checklist

• Capital Sufficiency: Verify the status of the $400,000 private placement and whether additional funding has been secured to meet the projected $500k-$1M development budget.
• Related Party Debt: Confirm the repayment status of the $23,120 owed to the director and whether it has been converted to equity or repaid.
• Merger Integration: Review the terms of the asset purchase agreement with Hamilton Atlantic and the license agreement with CRT to understand milestone payment obligations and equity dilution.
• Going Concern Status: Assess the company's ability to continue as a going concern given the accumulated deficit and lack of revenue.
• Stock Split Impact: Note the 24-for-1 forward stock split effected in March 2010 and ensure share counts are adjusted accordingly when analyzing ownership.